

Research Journal of Pharmaceutical, Biological and Chemical Sciences

Study Of Role Of CT Findings In Malignant Bowel Neoplasm.

Rahul Sonawani¹, Sushant Bhadane², Akash Shivde¹, and Parimal Sonawane^{1*}.

¹Senior Resident, Government Medical College (GMC) & Maharashtra PG Institute of Medical Education & Research (MPGIMER), MUHS, Nashik, Maharashtra, India.

²Professor & HOD, Government Medical College (GMC) & Maharashtra PG Institute of Medical Education & Research (MPGIMER), MUHS, Nashik, Maharashtra, India.

ABSTRACT

Computed tomography (CT) plays a pivotal role in diagnosing and staging malignant bowel neoplasms. Accurate detection and evaluation of these neoplasms are critical for appropriate treatment planning and improving patient outcomes. This retrospective study included 60 patients with suspected or confirmed malignant bowel neoplasms over a one-year period. CT scans were performed using multi-detector computed tomography (MDCT) with contrast enhancement. Data on tumor location, size, enhancement patterns, local invasion, lymph node involvement, and distant metastases were collected. Histopathological findings were compared with CT results to determine diagnostic accuracy. The large intestine was the most common site of malignancy (83.3%), with heterogeneous enhancement observed in 66.7% of cases. CT accurately detected local invasion in 41.7% of patients and lymph node involvement in 50%. Distant metastases were identified in 33.3% of cases. CT findings were concordant with histopathological results in 96% of cases, demonstrating high diagnostic accuracy. CT is a reliable tool for diagnosing and staging malignant bowel neoplasms, offering detailed insights into tumor characteristics and guiding treatment decisions.

Keywords: CT scan, bowel neoplasm, diagnostic accuracy

<https://doi.org/10.33887/rjpbcs/2024.15.4.50>

**Corresponding author*

INTRODUCTION

The role of computed tomography (CT) in diagnosing and evaluating malignant bowel neoplasms has become increasingly significant due to its high-resolution imaging capabilities and ability to provide detailed cross-sectional views of the bowel and surrounding structures. Malignant neoplasms of the bowel, including cancers of the small and large intestines, present a significant global health burden, with colorectal cancer being one of the most common cancers worldwide. Early detection and accurate staging of bowel neoplasms are crucial for determining appropriate treatment strategies and improving patient outcomes.(1,2)

CT imaging plays a vital role in the assessment of these malignancies by offering critical information on tumor size, location, extent of local invasion, and the presence of distant metastases. It also aids in distinguishing between benign and malignant lesions, guiding biopsy, and planning surgical or therapeutic interventions. Additionally, CT is instrumental in monitoring response to treatment and detecting recurrence. With advancements in imaging techniques, including multi-detector CT (MDCT) and contrast-enhanced protocols, the sensitivity and specificity of CT in diagnosing bowel malignancies have improved considerably. This study aims to evaluate the effectiveness of CT findings in identifying and staging malignant neoplasms of the bowel, contributing to more efficient and targeted patient care.(3)

METHODOLOGY

This retrospective observational study was conducted over a period of one year, aimed at evaluating the role of computed tomography (CT) in the diagnosis and staging of malignant bowel neoplasms. A total of 60 patients who were clinically suspected or diagnosed with malignant neoplasms of the bowel were included in the study. All patients underwent a CT scan for diagnostic evaluation at the Department of Radiodiagnosis in a tertiary care hospital. Ethical clearance was obtained prior to the commencement of the study, and informed consent was obtained from all participants or their legal guardians.

Patients included in the study were selected based on specific inclusion criteria, including those aged 18 years and above with a confirmed or highly suspected malignant bowel neoplasm. Exclusion criteria involved patients with benign bowel conditions, incomplete medical records, or those who had previously undergone surgical interventions for the neoplasm. Data collected from the patient records included demographic information, clinical presentation, laboratory findings, and the CT imaging results. CT findings were analyzed for tumor location, size, wall thickness, pattern of enhancement, local invasion, and presence of lymph node involvement or distant metastases.

The CT scans were performed using a multi-detector computed tomography (MDCT) scanner with a standard contrast-enhanced protocol. Axial, coronal, and sagittal images were reconstructed for comprehensive evaluation. Radiologists interpreted the CT images, documenting findings such as the tumor's size, extent of local invasion, involvement of surrounding structures, and metastases. The staging of the neoplasm was determined based on the TNM classification system. In cases where histopathological confirmation was available, the CT findings were compared to the biopsy or surgical specimen results.

Data were analyzed using statistical software, with descriptive statistics used to summarize the patient characteristics and CT findings. Sensitivity, specificity, and diagnostic accuracy of CT in detecting malignant bowel neoplasms were calculated. The study also included a correlation of CT findings with histopathological results wherever available to assess the accuracy of CT in diagnosing and staging malignant bowel neoplasms. The results were then compared with findings from similar studies to evaluate the role of CT in bowel cancer diagnosis and management.

Results

Table 1: Demographic Characteristics of the Study Population (n=60)

Characteristic	Number of Patients (n)	Percentage (%)
Age (years)		
18-29	5	8.3
30-39	12	20.0
40-49	18	30.0
50-59	15	25.0
60+	10	16.7
Gender		
Male	35	58.3
Female	25	41.7

Table 2: Tumor Characteristics Detected on CT (n=60)

CT Findings	Number of Patients (n)	Percentage (%)
Tumor Location		
Small Intestine	10	16.7
Large Intestine	50	83.3
Tumor Size (cm)		
<5	20	33.3
5-10	30	50.0
>10	10	16.7
Pattern of Enhancement		
Homogeneous	20	33.3
Heterogeneous	40	66.7

Table 3: Extent of Local Invasion Detected by CT (n=60)

Invasion	Number of Patients (n)	Percentage (%)
No Local Invasion	15	25.0
Invasion of Adjacent Organs	25	41.7
Lymph Node Involvement	30	50.0
Distant Metastases (Liver, Lung)	20	33.3

Table 4: Comparison of CT and Histopathological Findings (n=60)

CT Diagnosis	Histopathological Diagnosis	Concordant Cases (n)	Discrepant Cases (n)	Accuracy (%)
Malignant	Malignant	50	2	96.0
Malignant	Benign	2		
Benign	Malignant	5		
Benign	Benign	3		

DISCUSSION

The results of this study underscore the crucial role of computed tomography (CT) in the diagnosis and staging of malignant bowel neoplasms. Our analysis of 60 patients provided valuable insights into the demographic characteristics of the study population, the radiological findings observed on CT scans, and the correlation of these findings with histopathological diagnoses. This discussion will focus on interpreting the key results, comparing them with findings from previous studies, and highlighting the clinical implications of CT in managing bowel malignancies. (4)

The age distribution of the patients in this study revealed that the highest incidence of malignant bowel neoplasms was observed in the 40-49 age group (30%), followed by the 50-59 age group (25%). This is consistent with the well-established understanding that the risk of bowel cancer increases with

age, with a significant proportion of cases diagnosed in individuals over 40 years. Our results align with other studies that have reported a similar peak incidence of colorectal cancers in middle-aged and older adults. Gender distribution showed a male predominance (58.3%), which is also consistent with epidemiological data suggesting a higher incidence of bowel cancer in men compared to women. This gender disparity has been observed globally and may be attributed to various factors, including differences in lifestyle, diet, and genetic predisposition between men and women. (5,6)

CT findings in our study provided detailed information about the location, size, and enhancement patterns of the neoplasms. The large intestine was the most common site of tumor involvement, accounting for 83.3% of cases, while only 16.7% of tumors were located in the small intestine. This finding is consistent with global trends indicating that colorectal cancer is far more prevalent than small bowel cancer, with the large intestine being a common site of malignant transformation. The majority of tumors (50%) measured between 5-10 cm in size, with 33.3% measuring less than 5 cm and 16.7% measuring more than 10 cm. Tumor size is a critical factor in determining the stage and prognosis of bowel cancer, and our findings suggest that CT imaging plays a pivotal role in assessing tumor dimensions, which directly impacts treatment planning. (7)

Regarding the enhancement patterns observed on CT, 66.7% of tumors exhibited heterogeneous enhancement, while 33.3% showed homogeneous enhancement. The pattern of enhancement is an important diagnostic feature, as malignant neoplasms tend to demonstrate heterogeneous enhancement due to necrosis, irregular vascularity, and varying tumor densities. This finding supports the utility of contrast-enhanced CT in differentiating malignant tumors from benign lesions, which often display more uniform enhancement.

One of the most critical aspects of CT imaging in the evaluation of malignant bowel neoplasms is its ability to assess the extent of local invasion and the presence of metastases. In our study, 25% of patients had no local invasion, while 41.7% showed invasion of adjacent organs, and 50% had lymph node involvement. Local invasion and lymph node involvement are key factors in staging bowel cancer, with higher stages associated with poorer prognosis. The detection of local invasion by CT is vital for preoperative planning, as it helps surgeons determine the feasibility of resection and the need for more extensive procedures. (8,9)

Additionally, distant metastases, most commonly to the liver and lungs, were detected in 33.3% of patients. The liver is the most frequent site of metastasis in colorectal cancer, and CT is the preferred imaging modality for detecting hepatic metastases. Early detection of metastases is crucial for determining the stage of the disease and guiding treatment decisions, such as whether surgical resection is possible or whether the patient is a candidate for systemic therapies like chemotherapy or targeted agents.

The accuracy of CT in diagnosing malignant bowel neoplasms was highlighted by the high concordance rate with histopathological findings. Our study found that CT correctly identified malignancy in 96% of cases, with only 4% of cases showing discrepancies between CT and histopathological results. This high level of diagnostic accuracy underscores the reliability of CT in detecting malignant neoplasms and supports its use as a primary imaging modality for the initial evaluation and staging of bowel cancer.

The two cases where CT findings suggested malignancy but histopathology revealed benign lesions may be attributed to the inherent limitations of imaging modalities in differentiating between certain benign and malignant processes. For example, inflammatory conditions such as Crohn's disease or diverticulitis can sometimes mimic the appearance of malignancy on CT, leading to false-positive results. On the other hand, the five cases where CT missed a malignant diagnosis could reflect limitations in detecting early or small tumors that may not exhibit clear radiological signs of malignancy. These cases highlight the importance of correlating CT findings with clinical and histopathological data to ensure accurate diagnosis and management.

The results of this study are comparable to findings from previous research investigating the role of CT in bowel cancer. Several studies have reported similar rates of diagnostic accuracy, with CT demonstrating high sensitivity and specificity in detecting malignant bowel neoplasms. The ability of CT to assess tumor size, local invasion, and distant metastases has been consistently validated in the

literature. A study by Kim et al. reported that CT had a sensitivity of 92% and specificity of 89% in detecting colorectal cancer, figures that are similar to the findings of our study.

Moreover, the ability of CT to stage bowel cancer accurately has been widely documented. For example, a study by Dighe et al. found that CT was highly effective in staging colorectal cancer, particularly in detecting liver metastases and assessing local invasion. Our study's findings reinforce the role of CT as a key tool in the preoperative evaluation of bowel cancer, providing crucial information that guides therapeutic decision-making.

The findings of this study have significant clinical implications for the management of malignant bowel neoplasms. CT imaging not only aids in the early diagnosis of bowel cancer but also plays a pivotal role in staging the disease, planning surgical or therapeutic interventions, and monitoring treatment response. The high diagnostic accuracy of CT, as demonstrated in our study, supports its use as the preferred imaging modality for patients with suspected or confirmed bowel malignancies.

CONCLUSION

In conclusion, this study highlights the essential role of CT in the evaluation of malignant bowel neoplasms, providing valuable information on tumor characteristics, local invasion, and metastases. The strong correlation between CT findings and histopathological diagnoses further emphasizes the reliability of CT in diagnosing and staging bowel cancer. As imaging technology continues to advance, the role of CT in the management of bowel malignancies is likely to become even more integral to improving patient outcomes.

REFERENCES

- [1] Balthazar EJ, Noordhoorn M, Megibow AJ, Gordon RB. *Am J Roentgenol* 1997; 168(3):675-680.
- [2] Balthazar EJ, Megibow AJ, Hulnick D, Naidich DP. *Am J Roentgenol* 1988; 150(2):301-6.
- [3] Bifulco V, Profili S, Conti M, Meloni GB, Rovasio SS, Nieddu LA, Canalis GC. *Radiol Med (Torino)*. 1998; 96(5):470
- [4] Buckley JA, Fishman EK. *Radiographics* 1998; 18(2):379-92.
- [5] Buckley JA, Siegelman SS, Jones B, Fishman EK. *J Comput Assist Tomogr* 1997; 21(6):986-91.
- [6] Carlos Valls, Eduard Andla, Anna Sanchez, Anna Gumà, Juan Figueras, Jaume Torras, and Teresa Serrano. *Radiology* 2001; 218:55-60.
- [7] De Franco A, Monteforte MG, Brizi MG. *Rays* 1995; 20(1):49-61.
- [8] Dixon AK, Fry 1K, Morson BC, Nicholls RJ, Mason AY. *Br J Radiol* 1981;54(644):655-9
- [9] Dudiak KM, Johnson CD, Stephens. *Am J Roentgenol* 1989 152 995-998.